세계의 연구용 항체 및 시약 시장 예측 : 기술별, 용도별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Research Antibodies and Reagents Market is accounted for $12.83 billion in 2024 and is expected to reach $21.16 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Research antibodies and reagents are essential tools in scientific experiments, primarily in the fields of molecular biology, immunology, and biochemistry. Antibodies, which are proteins produced by the immune system, are specifically designed to bind to unique antigens, making them invaluable for detecting, identifying, and quantifying proteins or other molecules in various biological samples. Research reagents, on the other hand, refer to a broad range of substances that facilitate or enhance laboratory procedures, including buffers, enzymes, primers, and other chemicals used in experiments. These reagents help optimize the accuracy and reliability of experiments by providing the necessary chemical environment or biological components for reactions to occur.

According to CBRE Research, R&D expenditures by US life sciences companies have grown by ~ 40% over the past five years to reach nearly USD 154 billion in 2021.

Market Dynamics:

Driver:

Rising demand for personalized medicine

Personalized medicine, which tailors treatments based on an individual's genetic makeup, lifestyle, and specific disease characteristics, requires precise and targeted diagnostic tools. Research antibodies, which are essential for detecting specific proteins or biomarkers, and reagents that enable various laboratory procedures, play a crucial role in advancing personalized therapies. These antibodies and reagents are utilized in the development of genetic testing, biomarker discovery, and drug development, which are integral components of personalized medicine. The ability to accurately target disease mechanisms at a molecular level is pivotal in developing treatments that are more effective and have fewer side effects.

Restraint:

High cost of products

The high cost of research antibodies and reagents is a significant barrier to scientific progress, particularly in fields like immunology, biotechnology, and drug development. These essential tools, used for experiments such as diagnostics, protein analysis, and cell research, are often prohibitively expensive due to factors like limited production, high-quality control standards, and the cost of raw materials. Many academic institutions, small labs, and emerging researchers face budget constraints, making it difficult to access the required antibodies and reagents. This results in delayed projects, limited scope of experiments, and a slowdown in scientific advancements.

Opportunity:

Increased investment in cancer research

Increased investment in cancer research is driving significant advancements in the development of research antibodies and reagents, which are essential tools for understanding and targeting cancer at the molecular level. As cancer research continues to evolve, funding has allowed scientists to develop more specific, sensitive, and diverse antibodies, enhancing their ability to detect cancer markers and track tumor progression. These reagents are critical in both basic research and clinical settings, facilitating a deeper understanding of cancer biology, identifying new therapeutic targets, and improving diagnostics. The growing focus on immunotherapy and personalized medicine has further fueled the demand for high-quality antibodies, which can target specific cancer cells while minimizing damage to healthy tissue.

Threat:

Quality and specificity issues

The research antibodies and reagents market is facing significant challenges related to quality and specificity issues, which are hampering their effectiveness in scientific studies. Antibodies, crucial for detecting and analyzing proteins, often suffer from inconsistency in performance due to variations in manufacturing processes and inadequate validation. This results in poor reproducibility, where antibodies may bind to unintended targets, leading to inaccurate results. The lack of standardization in reagent formulations complicates experimental protocols, as researchers may face difficulty replicating results across different laboratories.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the research antibodies and reagents market, disrupting supply chains, research priorities, and manufacturing processes. During the height of the pandemic, many laboratories and research institutions shifted focus toward studying the virus, which led to an increased demand for antibodies, reagents, and diagnostic tools specific to COVID-19 detection and treatment. This situation forced many researchers to adapt by sourcing alternative reagents or modifying their research protocols. Despite these challenges, the pandemic also accelerated innovations in antibody and reagent development, especially for virus detection and vaccine research, which will likely have lasting benefits for future immunological studies and diagnostics.

The Flow Cytometry segment is expected to be the largest during the forecast period

Flow Cytometry segment is expected to dominate the largest share over the estimated period. Flow cytometry is a powerful tool used in immunology, cell biology, and diagnostics to analyze and sort cells based on their physical and chemical properties. The segment focused on enhancing research antibodies and reagents is crucial for improving the precision and reliability of flow cytometry techniques. By developing highly specific and optimized antibodies, researchers can target a wide range of cell surface markers and intracellular proteins, facilitating the study of complex biological processes. Innovations in reagents, such as fluorescence conjugates, buffers, and detection systems, further enhance the sensitivity, resolution, and accuracy of flow cytometry.

The Drug Development segment is expected to have the highest CAGR during the forecast period

Drug Development segment is estimated to grow at a rapid pace during the forecast period. The drug development sector is increasingly focusing on enhancing research antibodies and reagents to accelerate the discovery and development of new therapeutics. These antibodies and reagents play a critical role in understanding the underlying mechanisms of diseases, identifying potential drug targets, and validating therapeutic candidates. By improving the quality, specificity, and reliability of these tools, researchers can generate more accurate and reproducible data, which is essential for advancing drug discovery. Enhanced research antibodies help in precise biomarker detection, cell signaling pathway analysis and in vitro diagnostic applications.

Region with largest share:

North America region is poised to hold the largest share of the market throughout the extrapolated period. With continuous advancements in biotechnology, pharmaceuticals, and personalized medicine, the demand for high-quality antibodies and reagents has surged. These tools are crucial for the development of targeted therapies, biomarker identification, and diagnostics, especially in cancer, autoimmune diseases, and infectious diseases. North American researchers are leveraging cutting-edge techniques such as CRISPR and gene editing, which rely heavily on specialized reagents and antibodies. Additionally, increasing investment in research and development by pharmaceutical companies and academic institutions is further accelerating the demand across the region.

Region with highest CAGR:

Europe region is estimated to witness the highest CAGR during the projected time frame. By fostering collaborations between academic institutions, research organizations, and biotechnology companies, Europe has become a hub for cutting-edge developments in life sciences. These partnerships enable the sharing of expertise, resources, and technologies, which accelerates the discovery and optimization of high-quality antibodies and reagents. Additionally, joint ventures and collaborations with global industry leaders ensure access to the latest technologies and regulatory insights, promoting the development of more specific and effective research tools. As a result, European researchers benefit from a wider array of specialized products, enhancing their ability to conduct precise and impactful experiments.

Key players in the market

Some of the key players in Research Antibodies and Reagents market include Abcam Limited, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche AG, GE Healthcare Life Sciences, Merck Group, OriGene Technologies, PerkinElmer, Promega Corporation, SAB Biotherapeutics, Santa Cruz Biotechnology, Tecan Group, Thermo Fisher Scientific, Eppendorf AG and Lonza Group.

Key Developments:

In August 2023, Danaher (US) entered into a definitive agreement to acquire all the outstanding shares of Abcam plc (UK). Through this development, Abcam is expected to operate as a standalone operating company within Danaher's Life Sciences segment.

In August 2023, Agilent Technologies, Inc. (US) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia. The facility is focused on building local capabilities to accelerate research and development (R&D) in life science research.

Technologies Covered:

• Flow Cytometry
• Immunoprecipitation
• Western Blotting
• Multiplex Immunosorbent Assay
• Enzyme-Linked Immunosorbent Assay
• Other Technologies

Applications Covered:

• Drug Development
• Proteomics
• Genomics

End Users Covered:

• Pharmaceutical and Biotechnologies Industries
• Academic and Research Institutions
• Contract Research Organizations

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Research Antibodies and Reagents Market, By Technology

• 5.1 Introduction
• 5.2 Flow Cytometry
• 5.3 Immunoprecipitation
• 5.4 Western Blotting
• 5.5 Multiplex Immunosorbent Assay
• 5.6 Enzyme-Linked Immunosorbent Assay
• 5.7 Other Technologies

6 Global Research Antibodies and Reagents Market, By Application

• 6.1 Introduction
• 6.2 Drug Development
• 6.3 Proteomics
• 6.4 Genomics

7 Global Research Antibodies and Reagents Market, By End User

• 7.1 Introduction
• 7.2 Pharmaceutical and Biotechnologies Industries
• 7.3 Academic and Research Institutions
• 7.4 Contract Research Organizations

8 Global Research Antibodies and Reagents Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abcam Limited
• 10.2 Agilent Technologies, Inc
• 10.3 Bio-Rad Laboratories, Inc
• 10.4 F. Hoffmann-La Roche AG
• 10.5 GE Healthcare Life Sciences
• 10.6 Merck Group
• 10.7 OriGene Technologies
• 10.8 PerkinElmer
• 10.9 Promega Corporation
• 10.10 SAB Biotherapeutics
• 10.11 Santa Cruz Biotechnology
• 10.12 Tecan Group
• 10.13 Thermo Fisher Scientific
• 10.14 Eppendorf AG
• 10.15 Lonza Group